Fraunhofer ITEM: News

News / 12.1.2024

Reinforcing core competencies

Succession to Professor Thomas Thum to act as institute director of Fraunhofer ITEM and take up new role as chair of Toxicology at MHH.

News / 21.11.2023

Rapid therapies against viral diseases

As a finalist in the third round of the SPRIND Challenge, iGUARD receives follow-up funding of 2.5 million euros. 


Project / 19.9.2023

Environmental risk assessment (ERA)

Why does the environmental risk assessment for drugs need to be updated? 


Smart Health: Projekt "PrivacyUmbrella"

Ensure privacy of data through comprehensive deployment anonymization procedures.

News / 12.6.2023

Environmental assessment of chemicals

Final report published: Review of the OECD Test Guidelines.


News / 26.1.2024

Research on alternatives to animal studies on behalf of European Chemicals Agency (ECHA)

Scientific studies on the reliability and relevance of new approach methodologies (NAMs) as alternatives to animal studies.


Highlight / 18.9.2023

Toxicological risk assessment for PFAS

What amount of PFAS is it safe to ingest? At Fraunhofer ITEM, we are investigating how PFAS impact people’s health. 

Project / 29.6.2023

Project Genealyzer

Web application for the analysis and comparison of gene expression data.

Our research and development expertise

For more than four decades, we have been developing solutions for human health


Lung research

Research for healthy lungs: Airway research has been a focus at Fraunhofer ITEM ever since the institute was founded. 

Medical and pharmaceutical engineering

Next to innovative inhalation technologies, our focus is on developing novel technologies for administration of therapeutic aerosols by means of smart drug/device combination products.


Malignant disease research

The Fraunhofer ITEM Division of Personalized Tumor Therapy in Regensburg is aimed at understanding a patient’s individual condition, establishing appropriate diagnostics and optimizing therapies.

Bioinformatics and AI

Our researchers develop methods for preparation, analysis and visualization of biomedical data, as well as data models and data analysis pipelines. The focus is on the mapping of cellular and regulatory processes and their translation into applications.


RNA technologies

RNA-based therapeutics are a drug class with huge potential for medicine. Fraunhofer ITEM researchers develop novel drugs and methods for RNA-based therapeutic concepts.



Based on the next generation risk assessment concept, Fraunhofer ITEM develops new assessment strategies to provide predictive models for assessing the safety of compounds, active pharmaceutical ingredients and drugs.


Immunology and infection research

The development, formulation and mode of delivery of anti-infective agents, for example for inhaled administration as drug aerosols, are research topics of current interest at the institute.

Our services


Chemical Safety and Assessment


Translational Biomedical Engineering


Personalized Tumor Therapy

From molecular analysis to personalized therapy:


Fraunhofer ITEM

Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Nikolai-Fuchs-Strasse 1
30625 Hannover

Phone +49 511 5350-0



Models of Lung Disease 2024

Please save the date for the 22nd Fraunhofer Seminar "Models of Lung Disease". We would be pleased to welcoming you there.
more info


GPTS 2024

This year’s 9th German Pharm-Tox Summit will be held in Munich (Germany) from March 13 to 15, 2024. Scientists from Fraunhofer ITEM will contribute four presentations and nine posters.
more info


SOT Annual Meeting and ToxExpo 2024 in Salt Lake City

We are excited to be at this year’s SOT Annual Meeting and ToxExpo in Salt Lake City, Utah (USA), and will be very happy to share insights into our latest toxicology research with you. Booth number: 817
more info


BIO-Europe 2023

The international gathering of biopharma professionals BIO-Europe® will take place in Munich, Germany, from November 6 to 8, 2023.
more info

About Fraunhofer ITEM

The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is one of 76 institutes and research institutions of the Fraunhofer-Gesellschaft, the world’s leading applied research organization. Protecting man from health hazards in our industrialized world and contributing to the development of novel therapeutic approaches are the aims Fraunhofer ITEM is pursuing with its contract research. With a focus on lung research, our R&D portfolio includes three business areas: Drug Development, Chemical Safety and Translational Biomedical Engineering. In addition, our scientists in Regensburg do research in the field of personalized tumor therapy.

With a staff of around 450 at its locations in Hannover, Braunschweig and Regensburg, the institute cooperates with industry, service providers, and public authorities in projects that drive economic development and serve the wider benefit of society.


More information about Fraunhofer ITEM